600161.SS SHH
Beijing Tiantan Biological Products Co., Ltd.
1W: +1.9%
1M: +2.9%
3M: +4.7%
YTD: -23.7%
1Y: -37.9%
3Y: -38.6%
5Y: -43.0%
¥12.59 ($1.88)
+0.47 (+3.88%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$6.1B
+1.8% ▲
5Y CAGR: +12.2%
Gross Profit
$2.6B
-21.7% ▼
5Y CAGR: +8.8%
Operating Income
$1.8B
-30.9% ▼
5Y CAGR: +9.8%
Net Income
$1.1B
-29.6% ▼
5Y CAGR: +11.3%
EPS (Diluted)
$0.55
-29.5% ▼
5Y CAGR: -2.7%
EBITDA
$2.2B
-20.1% ▼
5Y CAGR: +13.4%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $4.1B | $4.3B | $5.2B | $6.0B | $6.1B |
| YoY Growth | +19.3% | +3.6% | +21.6% | +16.4% | +1.8% |
| Cost of Revenue | $2.2B | $2.2B | $2.6B | $2.7B | $3.6B |
| Gross Profit | $2.0B | $2.1B | $2.6B | $3.3B | $2.6B |
| Gross Margin | 47.5% | 49.0% | 50.7% | 54.6% | 42.0% |
| R&D Expenses | $133M | $122M | $140M | $173M | $148M |
| SG&A Expenses | $599M | $407M | $739M | $397M | $602M |
| Operating Expenses | $709M | $657M | $823M | $735M | $813M |
| Operating Income | $1.2B | $1.4B | $1.8B | $2.6B | $1.8B |
| Operating Margin | 30.3% | 33.6% | 34.8% | 42.4% | 28.8% |
| Interest Expense | $3M | $4M | $6M | $8M | $10M |
| Income Before Tax | $1.2B | $1.4B | $1.8B | $2.5B | $1.8B |
| Tax Expense | $172M | $222M | $289M | $435M | $333M |
| Net Income | $760M | $881M | $1.1B | $1.5B | $1.1B |
| Net Margin | 18.5% | 20.7% | 21.4% | 25.7% | 17.8% |
| EPS (Diluted) | $0.67 | $0.73 | $0.56 | $0.78 | $0.55 |
| EBITDA | $1.3B | $1.5B | $2.0B | $2.8B | $2.2B |
| Shares Outstanding | 1.60B | 1.65B | 1.98B | 1.99B | 1.98B |